Year in Review: Multiple Myeloma

(MedPage Today) -- Advances in multiple myeloma treatment this year were marked by the resurrection of a drug that had been previously pulled off the market, new FDA approvals, and research suggesting that an isatuximab (Sarclisa)-based quadruplet...